Currently, there are 50.47M common shares owned by the public and among those 48.24M shares have been available to trade.
Insiders at the company have transacted a total of 27 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 14 of these insider trades were purchases, accounting for 96,879 shares. Insider sales of the common stock occurred on 13 occasions, with total insider shares sold totaling 129,055 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 51.90, up 1.11%. The company’s stock has a 5-day price change of 0.06% and 51.79% over the past three months. PRCT shares are trading 19.23% year to date (YTD), with the 12-month market performance up to 35.71% higher. It has a 12-month low price of $24.83 and touched a high of $51.39 over the same period. PRCT has an average intraday trading volume of 485.04K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.12%, 11.84%, and 39.65% respectively.
Institutional ownership of Procept BioRobotics Corp (NASDAQ: PRCT) shares accounts for 90.20% of the company’s 50.47M shares outstanding.
It has a market capitalization of $2.52B and a beta (3y monthly) value of 1.03. The earnings-per-share (ttm) stands at -$2.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.10% over the week and 4.75% over the month.
Analysts forecast that Procept BioRobotics Corp (PRCT) will achieve an EPS of $Arcturus Therapeutics Holdings for the current quarter, $36.92 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Direct Digital Holdings, Inc. while analysts give the company a high EPS estimate of $PROVECTUS BIOPHARMACEUTICALS IN. Comparatively, EPS for the current quarter was $Porch Group, Inc. a year ago. Earnings per share for the fiscal year are expected to decrease by -9.06%, and 11.61% over the next financial year.
Looking at the support for the PRCT, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on August 11, 2023, with the firm’s price target at $42.
